Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis induce sustained clinical responses in a sizable minority of cancer patients. We found that primary resistance to ICIs can be attributed to abnormal gut microbiome composition. Antibiotics inhibited the clinical benefit of ICIs in patients with advanced cancer. Fecal microbiota transplantation (FMT) from cancer patients who responded to ICIs into germ-free or antibiotic-treated mice ameliorated the antitumor effects of PD-1 blockade, whereas FMT from nonresponding patients failed to do so. Metagenomics of patient stool samples at diagnosis revealed correlations between clinical responses to ICIs and the relative abundance of Akkermansia muciniphila. Oral supplementation with A. muciniphila after FMT with nonresponder feces restored the efficacy of PD-1 blockade in an interleukin-12-dependent manner by increasing the recruitment of CCR9 + CXCR3 + CD4 + T lymphocytes into mouse tumor beds.
C
ancer immunotherapy has become highly successful against an array of distinct hematological and solid metastatic malignancies (1) (2) (3) (4) (5) (6) . Administration of immune checkpoint inhibitors (ICIs) unleashes T lymphocytemediated immune responses by suppressing the interaction of T cell inhibitory receptors with their cognate ligands on tumor or stromal cells (7) . The most widely used ICIs are monoclonal antibodies (mAbs) targeting programmed cell death protein 1 (PD-1) and its ligand PD-L1 (7). PD-1 blockade is highly efficacious against advanced melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). Primary resistance, observed in 60 to 70% of cases (3, 5, 8) , has been attributed to low mutational burden, poor intrinsic antigenicity of tumor cells (9, 10) , absence of priming by potentially immunogenic pretreatment with chemo-or radiotherapy (11) , defective antigen presentation during the priming phase (12) , local immunosuppression by extracellular metabolites (13) , and functional exhaustion of tumor-infiltrating lymphocytes (13) (14) (15) .
Recent work in mice has highlighted the key role of the gut microbiota in mediating tumor responses to chemotherapeutic agents and immunotherapies targeting PD-L1 or cytotoxic T lymphocyte-associated protein 4 (CTLA-4) (16) (17) (18) (19) (20) (21) . Therefore, we explored the possibility that dysbiosis associated with malignant disease or concomitant antibiotic (ATB) use could influence primary resistance to PD-1 blockade in tumorbearing mice and cancer patients.
Initially, we compared the therapeutic efficacy of PD-1 mAb alone or combined with CTLA-4 mAb in mice with established MCA-205 sarcoma and RET melanoma. Mice were reared in specific pathogen-free (SPF) conditions and treated for 14 days with broad-spectrum combination ATB (ampicillin + colistin + streptomycin) or left untreated. ATB treatment significantly compromised the antitumor effects and survival of mice treated with PD-1 mAb alone or in combination with CTLA-4 mAb (Fig. 1, A and B) .
We next addressed the impact of ATB on patients with advanced NSCLC (n = 140), RCC (n = 67), or urothelial carcinoma (n = 42) who received PD-1/PD-L1 mAb after one or several prior therapies. Out of all 249 patients, 69 (28%) were prescribed ATB (b-lactam +/− inhibitors, fluoroquinolones, or macrolides) within 2 months before, or 1 month after, the first administration of PD-1/PD-L1 mAb. Patients generally took ATB orally for common indications (dental, urinary, and pulmonary infections). There were no major statistical differences in baseline clinical characteristics between ATB-treated and untreated patients (tables S1 to S6). Progression-free survival (PFS) and overall survival (OS) were significantly shorter in the ATB-treated group when all patients were combined (Fig. 1C) . Similarly, PFS and/or OS were shorter in ATB-treated groups when individual tumor types were considered (Fig. 1, D and E, and fig. S1 , A to C). In univariate and multivariate Cox regression analyses, ATB represented a predictor of resistance to PD-1 blockade, independent from classical prognostic markers in NSCLC and RCC (tables S7 to S9). A validation cohort of 239 advanced NSCLC patients confirmed the negative impact of ATB uptake on OS during PD-1/PD-L1 inhibition ( fig. S1D ). In contrast, proton pump inhibitors, a medication that can also alter the microbiota composition, failed to affect PFS or OS in these patients ( fig.  S2) (22) . On the basis of previous observations that ATB can transiently change the composition of the gut microbiome (23), we hypothesized that dysbiosis might affect the therapeutic efficacy of ICIs.
To explore the composition of the gut microbiota, we used quantitative metagenomics by shotgun sequencing, reaching >20 million short DNA sequence reads per sample, followed by analysis of the results in a reference catalog of 9.9 million genes (24) . Total DNA was extracted from 100 patients diagnosed with NSCLC (n = 60) and RCC (n = 40) before starting therapy and serially after PD-1 blockade (tables S10 to S13). The higher richness of the samples evaluated at the gene count or metagenomic species (MGS) levels correlated with the clinical response defined by the absence of progression of disease, 6 months after initiation of ICIs based on RECIST 1.1 criteria ( Fig. 2A) (25) . Stool richness increased at the MGS level over the course of therapy, more in RCC patients than in NSCLC patients ( fig. S3 ). For each sample, MGS occurrence was visualized using "barcodes" (i.e., heat maps reflecting the abundance of 50 marker genes for each MGS) ( fig. S4 ). The taxonomical annotation of each MGS was based on gene homology to previously sequenced organisms (using blastN against the nucleotide and whole-genome shotgun data banks).
When segregating responders (R) from nonresponders (NR) (according to the best clinical response as assessed by RECIST1.1), we observed an overrepresentation of unclassified and classified Firmicutes, as well as distinct bacterial genera (such as Akkermansia and Alistipes) (Fig. 2B  and fig. S4 ). The commensal that was most significantly associated with favorable clinical outcome in both NSCLC and RCC was A. muciniphila (P = 0.004 considering all patients, P = 0.003 excluding ATB-treated patients) ( Fig. 2B; fig. S4 , A and B; and tables S10 to S13). When analyzing PFS according to RECIST 1.1, A. muciniphila was also enriched in patients with PFS longer than 3 months relative to those with PFS shorter than 3 months, both in the whole cohort (P = 0.028, fig. S5A ) and when excluding patients on ATB (P = 0.007; Fig. 2C and fig. S5B ). A. muciniphila was also enriched when analyzing the NSCLC cohort alone (P = 0.045 with or without ATB, fig.  S6A ; P = 0.026 excluding ATB, fig. S6B ) along with other commensals such as Ruminococcus spp., Alistipes spp., and Eubacterium spp., with a relative underrepresentation of Bifidobacterium adolescentis, B. longum, and Parabacteroides distasonis. More precisely, the fecal presence of A. muciniphila was detectable in 69% (11/16) and 58% (23/40) of patients exhibiting a partial response or stable disease, respectively, whereas it could only be detected in 34% (15/44) of patients who progressed or died (P = 0.007, Fig.  2D) . A validation cohort of 53 patients (27 NSCLC and 26 RCC) confirmed that A. muciniphila was enriched in patients with the best clinical response and PFS longer than 3 months (fig. S7 and table S14). These findings show that A. muciniphila was overrepresented at diagnosis in the feces of patients who later benefited from PD-1 inhibition.
In an attempt to link gut microbial content to systemic immune tone, we analyzed memory T cell responses from peripheral blood, elicited against microbiota after the initiation of PD-1 blockade. The recall response of circulating CD4 + and CD8 + T cells harvested from 27 NSCLC and 28 RCC patients under PD-1 blockade was measured upon coculture with autologous monocytes preincubated with distinct commensals (Fig. 2E and tables S15 and S16). In this setting, the secretion of cytokines by major histocompatibility complex class II-restricted CD4 + T cells (Th1, Th22, or Tr1) was quantified (figs. S8 and S9). The only immune responses that correlated with the clinical outcome during PD-1 mAbtargeted ICI were the Th1 (Fig. 2F) and Tc1 ( fig. S10A ) cell reactivity against A. muciniphila, interferon-g (IFN-g) release above the median being associated with prolonged PFS. In contrast, no association was found between clinical outcome and IFN-g, interleukin-10 (IL-10), or IL-22 secretion stimulated by nonspecific cross-linking of the T cell receptor ( fig. S10B ) or memory T cell responses to 10 other commensals with the exception of Enterococcus hirae 13144 (E. hirae) for the Tc1 response (Fig. 2F) , as previously reported (19) . We also observed a higher incidence of cultivatable E. hirae in R NSCLC patients than in NR NSCLC patients among 32 stool samples tested at diagnosis (Fig. 2G) , further supporting the relevance of E. hirae to predict best clinical outcome.
To establish a cause-effect relationship between the anticancer efficacy of PD-1 blockade and the dominance of distinct commensal species in clinical responses, we recolonized ATB-treated mice reared in SPF conditions (or, alternatively, germ-free animals) by fecal microbiota transplantation (FMT) using patient stool. Such "avatar mice" were prepared by oral gavage of feces harvested at diagnosis from eight different NSCLC patients, four R and four NR (defined using best clinical outcome). Two weeks later, C57BL/6 avatar mice were inoculated with MCA-205 tumor cells, then treated 5 days later with PD-1 mAb (Fig. 3A) . Stool samples from clinical R conferred sensitivity, whereas those from NR patients conveyed resistance to PD-1 blockade with a similar efficiency in ATB-treated or germ-free avatar mice ( Fig. 3B and table S17 ). Although stool composition failed to influence the natural progression of MCA-205 sarcomas, it did so after PD-1 blockade (Fig. 3C) . FMT from R patients (but not from NR patients) into avatar mice caused tumor growth delay (Fig. 3C, center and right) , accumulation of CXCR3 + CD4 + T cells in the tumor microenvironment (Fig. 3D) , and up-regulation of PD-L1 in splenic T cells (Fig. 3E) after PD-1 blockade. These findings could be corroborated by FMT from seven RCC patients into ATB-treated BALB/c mice that were then orthotopically implanted with luciferase-expressing renal cancer (RENCA) cells resistant to PD-1 monotherapy and treated with a combination of CTLA-4 and PD-1 mAbs ( fig. S11 and table S18 ). Bioluminescence monitoring revealed that stool samples from R patients restored the antitumor activity of simultaneous CTLA-4 and PD-1 blockade, unlike those from NR patients (Fig. 3F) . Together, these results suggest that the intestinal microbiota from patients influences the outcome of ICIs in avatar mice.
To validate the biological importance of the microbiota identified in the metagenomic analysis of patients with a favorable clinical outcome, we colonized intestines from mice with A. muciniphila alone or combined with other commensals in several conditions of gut dysbiosis. First, ATBmediated sterilization of the microbiome was followed by natural recolonization supplemented with five oral gavages of A. muciniphila, alone or together with the goblet cell-stimulating E. hirae (17, 19) , in an attempt to restore responsiveness to PD-1 blockade in RET melanoma-bearing hosts reared in SPF conditions. A. muciniphila alone or combined with E. hirae reinstated the anticancer effects of PD-1 blockade that were previously inhibited by ATB (Fig. 1A, Fig. 4A, and fig.  S12A ). Second, we used an orthotopic luciferaseexpressing Lewis lung carcinoma (LLC) model amenable to combination treatment by local radiotherapy and PD-1 blockade (26) . Again, oral gavages with A. muciniphila and E. hirae increased the efficacy of PD-1 blockade with respect to tumor growth, as measured by whole-body imaging (Fig. 4B) . Finally, we confirmed that monocolonization with A. muciniphila or bicolonization of A. muciniphila plus E. hirae reversed the compromised efficacy of PD-1 blockade observed after the recolonization of germ-free or ATB-treated SPF mice with FMT from NR patients ( Fig. 4C and fig. S12B ). In addition to this, Alistipes indistinctus, which was found to be overrepresented among NSCLC responders, was efficient in restoring the efficacy of this ICI in avatar mice (Fig. 4C and fig. S12 ); other unrelated commensals failed to do so ( fig. S13) .
Next, we analyzed the immunological changes elicited by oral gavage with a combination of A. muciniphila and E. hirae in mesenteric lymph nodes (mLN), tumor draining LN (dLN), and tumor beds. Central memory (TCM) CD4 + T cells expressing the small intestine-associated chemokine receptor CCR9 and/or the Th1-associated chemokine receptor CXCR3 accumulated 48 hours after the first injection in mLN (Fig. 4D ) and were observed in dLN ( fig. S14A ) and tumor beds upon killing (Fig. 4E and fig. S14 , B and C). Immunohistochemical studies revealed the formation of intratumoral granulomas ( fig. S15 ) and increased CD4/Foxp3 ratios in tumors from animals cotreated with PD-1 mAb and A. muciniphila (Fig. 4,  F and G) . Moreover, A. muciniphila and E. hirae (19) induced dendritic cells to secrete IL-12 ( fig.  S16A ), a Th1 cytokine involved in the immunogenicity of PD-1 blockade in eubiotic conditions (Fig. 4H, left, and fig. S16B ) as well as in the adjuvant effects of A. muciniphila in dysbiotic settings (Fig. 4H, right) , as previously shown for B. fragilis in the context of CTLA-4 blockade (20) .
Our findings show that the gut microbiome markedly influences the outcome of PD-1 blockade in mice and patients. Several issues remain unresolved. The mechanisms accounting for the immunomodulatory effects of A. muciniphila, one of the most abundant bacteria in the ileum microbiota, remain unclear (27) . Cancer patients face stresses that can cause gut barrier dysfunction and systemic endotoxemia. By reinforcing intestinal barrier integrity and reducing systemic inflammation, A. muciniphila, Clostridiales, and Ruminococcaceae might generate "homeostatic" consortia of commensals that prevent leaky colon and systemic immunosuppression (28) (29) (30) . In parallel, unleashing T cells by PD-1 blockade alleviated small intestine tolerance, thereby eliciting local and systemic recall Th1 immune responses against A. muciniphila that might improve cancer immunosurveillance. Finally, a comprehensive analysis of stool composition after a chronic shift of the microbiome enforced by commensals endowed with anticancer effects might unveil further functional links between the microbial ecosystem and anticancer immunosurveillance (28) . Irrespective of these remaining questions, our findings suggest that the microbiome governs the cancerimmune set point of cancer-bearing individuals (30) and that manipulating the gut ecosystem to circumvent primary resistance to ICIs may become feasible.
